Clinical trials: Movement Abnormalities
Parkinson's Disease, Levodopa Induced Dyskinesia (LID)
Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia
The purpose of a randomized, double-blind, placebo-controlled, 2-way crossover study is to evaluate the efficacy, safety/tolerability and pharmacokinetics of JM-010 for the treatment of subjects with Parkinson's Disease (PD) with…
- Trial name
- LID (NCT02439203)
- Testing
- JM-010
- Where
- South Africa
- Volunteers
- 30 people
- Sponsor
- Bukwang Pharmaceutical
Parkinson Disease
Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease
An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease
- Trial name
- NCT02542696
- Testing
- APL-130277
- Where
- 70 sites in United States, Austria and 6 more
- Volunteers
- 496 people
- Sponsor
- Sumitomo Pharma America, Inc.
Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy
Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
The purpose of this study is to assess the durability of effect of Droxidopa in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy…
- Conditions
- Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy, Multiple System Atrophy, Dopamine Beta Hydroxylase Deficiency
- Trial name
- NOH303 (NCT00738062)
- Testing
- Droxidopa
- Where
- 54 sites in United States, Australia and 2 more
- Volunteers
- 103 people
- Sponsor
- Chelsea Therapeutics
Parkinson Disease
Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)
This is a double blind, placebo-controlled clinical trial of 15 months duration designed to examine early Mirapex (pramipexole) treatment vs. delayed Mirapex (pramipexole) treatment in patients with new onset Parkinsons disease
- Trial name
- NCT00321854
- Testing
- pramipexole
- Where
- 99 sites in United States, Austria and 8 more
- Volunteers
- 535 people
- Sponsor
- Boehringer Ingelheim
Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB)
Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies
Progressive supranuclear palsy (PSP), mild cognitive impairment with Lewy bodies (MCI-LB), and Dementia with Lewy Bodies (DLB) are severe neurodegenerative diseases that cause significant motor impairment impacting daily…
- Conditions
- Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB), PSP, Lewy Body Dementia (LBD)
- Trial name
- NCT07240805
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- BioSensics
Parkinson Disease
Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants
The primary purpose of this study is to evaluate the effect of carbamazepine, a strong CYP3A4 inducer, on the steady-state pharmacokinetics (PK) of tavapadon in healthy adult participants.
- Trial name
- NCT05581823
- Testing
- Tavapadon, Carbamazepine
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Cerevel Therapeutics, LLC
Parkinson Disease, Movement Disorders
Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease
This study evaluates the safety and tolerability of CDNF in patients with Parkinson's disease, when dosed directly into the brain using an implanted investigational drug delivery system (DDS).
- Conditions
- Parkinson Disease, Movement Disorders, Neurodegenerative Diseases, Nervous System Diseases
- Trial name
- NCT03295786
- Testing
- Cerebral Dopamine Neurotrophic Factor, Renishaw Drug Delivery System
- Where
- 3 sites in Finland, Sweden
- Volunteers
- 17 people
- Sponsor
- Herantis Pharma Plc.
Tardive Dyskinesia
Studying Patterns in Patient Engagement Among Tardive Dyskinesia Patients
The statistical analysis of the collected data aims to reveal the many factors that influence patient involvement in clinical trials.
- Trial name
- NCT06218719
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Parkinson Disease
Development of Software to Provide the SpeechVive Device Via the Internet
Telehealth, increasingly recognized in the neurology field as a solution to access issues for people with Parkinson's disease, improves access to speech therapy, particularly those living in rural areas or with travel barriers.
- Trial name
- NCT02744911
- Testing
- SpeechVive device, Telemedicine interaction, In person interaction
- Where
- 2 sites in United States
- Volunteers
- 143 people
- Sponsor
- SpeechVive, Inc
Huntington Disease
The Safety and Tolerability Study With ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease
This is an open label, dose escalation clinic trial of ER2001 intravenous injection to evaluate safety, tolerability and pharmacokinetics of ascending single and multiple doses of intravenously administered ER2001 in patients…
- Trial name
- NCT06024265
- Testing
- ER2001 injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- ExoRNA Bioscience
Progressive Supranuclear Palsy
A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)
The purpose of the study is to assess the safety and tolerability of UCB0107 in study participants with Progressive Supranuclear Palsy (PSP).
- Trial name
- NCT04185415
- Testing
- bepranemab
- Where
- 13 sites in Belgium, Germany and 2 more
- Volunteers
- 25 people
- Sponsor
- UCB Biopharma SRL
Parkinson Disease (PD)
VG081821AC Tablets for Early to Mid-stage Parkinson's Disease
This study is testing a new oral medication called VG081821AC to see if it can help improve movement symptoms in people with early to mid-stage Parkinson's disease.
- Trial name
- NCT07725562
- Testing
- VG081821AC
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Zhejiang Vimgreen Pharmaceuticals, Ltd.
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including…
- Conditions
- Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- MERIT (NCT07892651)
- Where
- Jordan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Axiom Bioregistry
Alzheimer Disease, Mild Cognitive Impairment
Longitudinal Cognitive Assessment by BoCA
The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Vascular Dementia, Frontotemporal Dementia
- Trial name
- BoCA (NCT04114994)
- Testing
- Boston Cognitive Assessment (BoCA)
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Alzheimer's Light LLC
Tourette's Disorder, Tic Disorder
Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
The goal of the current trial is to determine efficacy and safety of Once-daily aripiprazole in reducing Total Tic Severity in children and adolescents with Tourette's Disorder.
- Trial name
- NCT01727700
- Testing
- Aripiprazole
- Where
- 75 sites in United States, Canada and 7 more
- Volunteers
- 133 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Parkinson's Disease
Outcomes Data of Adipose Stem Cells to Treat Parkinson's Disease
The purpose of this study is to determine the impact that treatment with a cellular concentrate derived from an individual's own fat, known as the stromal vascular fraction (SVF), has on the quality of life of people with…
- Trial name
- NCT02184546
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- StemGenex
Parkinson's Disease
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Patients With Parkinson's Disease
A phase Ⅰ/Ⅱ study to evaluate the tolerability, safety, and efficacy of VGN-R09b in pa-tients with Parkinson's disease
- Trial name
- NCT06480461
- Testing
- VGN-R09b
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.
Essential Tremor, Parkinson's Disease
Global Registry: ExAblate Neuro MR Guided Focused Ultrasound (MRgFUS) of Neurological Disorders:
A global post approval study to collect safety and effectiveness data related to ExAblate Neuro for the treatment of certain disorders such as Essential Tremor, Parkinson's Movement Disorders, or Neuropathic Pain within the…
- Conditions
- Essential Tremor, Parkinson's Disease, Movement Disorders, Neuropathic Pain
- Trial name
- NCT03100474
- Where
- 9 sites in United States, Canada and 2 more
- Volunteers
- 500 people
- Sponsor
- InSightec
Parkinson Disease, Gait Disorders, Neurologic
Digital GaitCare - Therapy Monitoring in the Home Environment of Patients With Parkinson
Gait disturbances and movement restrictions occur frequently in Parkinson's disease. Patient-centered monitoring with objective aids in the patient's daily life, supports and promotes therapy decisions made by physicians and…
- Trial name
- NCT04931303
- Where
- 5 sites in Germany
- Volunteers
- 31 people
- Sponsor
- Medical Valley Digital Health Application Center GmbH
Parkinson Disease
Evaluation of the Personal KinetiGraph™ (PKG™) to Improve Insight Into Parkinson's Disease Status
The primary objective is to understand the utility of Personal KinetiGraph movement recording system data in the clinical management of Parkinson's disease (PD) in routine clinical care at a movement disorders clinic.
- Trial name
- APPRISE (NCT03741920)
- Testing
- Personal KinetiGraph™ (PKG™)
- Where
- 12 sites in United States
- Volunteers
- 231 people
- Sponsor
- Global Kinetics Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.